Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma : A real-world study using Taiwan Head Neck Society registry database
© 2024 Wiley Periodicals LLC..
BACKGROUND: For R/M HNSCC, the differences in prognosis and treatment options between distant metastasis (DM) and locoregional recurrence, especially in the DM group, remain unclear.
METHODS: From the Taiwan Head Neck Society registry database, patients who were diagnosed with R/M HNSCC and received cetuximab-based frontline therapy were collected for analysis.
RESULTS: Among the enrolled patients, 59.3% (491/827) belonged to the DM group. The DM group had less primary site of oral cavity, less betel nut chewing, higher lactate dehydrogenase (LDH) levels, and higher LDH/albumin ratio compared with the non-DM group. For the patients with primary site of oral cavity and current smokers, DM coexisted with poorer outcomes. In the DM group, EXTREME-like regimen was more suitable for older patients, those with elevated LDH, and those with higher LDH/albumin ratio than TPExtreme-like regimen.
CONCLUSION: DM coexisted with poorer prognosis in certain groups. LDH-associated biomarkers may aid treatment options for DM patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:46 |
|---|---|
| Enthalten in: |
Head & neck - 46(2024), 5 vom: 11. Apr., Seite 1063-1073 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lu, Hsueh-Ju [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Albumins |
|---|
| Anmerkungen: |
Date Completed 10.04.2024 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/hed.27681 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368759792 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368759792 | ||
| 003 | DE-627 | ||
| 005 | 20240410232541.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hed.27681 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM368759792 | ||
| 035 | |a (NLM)38385970 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lu, Hsueh-Ju |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical outcomes of cetuximab-based treatment for distant metastatic head and neck squamous cell carcinoma |b A real-world study using Taiwan Head Neck Society registry database |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.04.2024 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 Wiley Periodicals LLC. | ||
| 520 | |a BACKGROUND: For R/M HNSCC, the differences in prognosis and treatment options between distant metastasis (DM) and locoregional recurrence, especially in the DM group, remain unclear | ||
| 520 | |a METHODS: From the Taiwan Head Neck Society registry database, patients who were diagnosed with R/M HNSCC and received cetuximab-based frontline therapy were collected for analysis | ||
| 520 | |a RESULTS: Among the enrolled patients, 59.3% (491/827) belonged to the DM group. The DM group had less primary site of oral cavity, less betel nut chewing, higher lactate dehydrogenase (LDH) levels, and higher LDH/albumin ratio compared with the non-DM group. For the patients with primary site of oral cavity and current smokers, DM coexisted with poorer outcomes. In the DM group, EXTREME-like regimen was more suitable for older patients, those with elevated LDH, and those with higher LDH/albumin ratio than TPExtreme-like regimen | ||
| 520 | |a CONCLUSION: DM coexisted with poorer prognosis in certain groups. LDH-associated biomarkers may aid treatment options for DM patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarkers | |
| 650 | 4 | |a cetuximab | |
| 650 | 4 | |a distant metastasis | |
| 650 | 4 | |a head and neck squamous cell carcinoma | |
| 650 | 4 | |a lactate dehydrogenase | |
| 650 | 7 | |a Cetuximab |2 NLM | |
| 650 | 7 | |a PQX0D8J21J |2 NLM | |
| 650 | 7 | |a Albumins |2 NLM | |
| 700 | 1 | |a Hsieh, Meng-Che |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hung-Ming |e verfasserin |4 aut | |
| 700 | 1 | |a Hsieh, Jason Chia-Hsun |e verfasserin |4 aut | |
| 700 | 1 | |a Yen, Chia-Jui |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Shang-Yin |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Huai-Cheng |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hui-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Pen-Yuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Tien-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Chien, Chih-Yen |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Tai-Lin |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Yi-Fang |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Chun-Hung |e verfasserin |4 aut | |
| 700 | 1 | |a Lien, Ming-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jo-Pai |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Wei-Chen |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jin-Ching |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Chen-Chi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yi-Chun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Muh-Hwa |e verfasserin |4 aut | |
| 700 | 1 | |a Lou, Pei-Jen |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Head & neck |d 1996 |g 46(2024), 5 vom: 11. Apr., Seite 1063-1073 |w (DE-627)NLM012791806 |x 1097-0347 |7 nnns |
| 773 | 1 | 8 | |g volume:46 |g year:2024 |g number:5 |g day:11 |g month:04 |g pages:1063-1073 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hed.27681 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 46 |j 2024 |e 5 |b 11 |c 04 |h 1063-1073 | ||